peritoneal dialysis patients
Conditions
Interventions
Start with once-daily dosing of vildagliptin 50mg, and increase up to twice a day 50 mg if effect of vilidagliptin on the clinical parameters is insufficient.
Sponsors
Department of Nephrology, Fujita Health University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: ESRD patients under CAPD treatment for more than three months
Exclusion criteria
Exclusion criteria: Acute renal failure, severe liver dysfunction, peritonitis, perioperative patients , serious trauma, unstable heart disorder or cerebrovascular disease, infection, malignant tumor, pregnant women or women suspected of being pregnant, the subjects found offensive by attending physicians for this research, hypersensitivity with the DPP-4 inhibitor, history of diabetic ketoacidosis or diabetic coma, type I diabetes mellitus, taking the drug which is contraindicated to combination vildagliptin
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Plasma glucose profiling using CGM | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) blood parameters: CBC, biochemistry, HbA1c, GA, beta2 MG, MDA-LDL 2) fasting glood glusoce 3) ABI 4) peritoneal equilibration test | — |
Countries
Japan
Contacts
Public ContactShigehisa Koide
Fujita Health University School of Medicine Department of Nephrology
Outcome results
None listed